Genomictree Inc. (KOSDAQ:228760)

Market Cap	566.80B
Revenue (ttm)	3.56B
Net Income (ttm)	-9.10B
Shares Out	24.02M
EPS (ttm)	-379.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	131,565
Average Volume	197,162
Open	23,200
Previous Close	23,200
Day's Range	23,050 - 23,950
52-Week Range	11,390 - 24,500
Beta	0.07
RSI	73.11
Earnings Date	Nov 10, 2025

About Genomictree

Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraDTect SARS-CoV-2 RT-qPCR...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 77
• Stock Exchange: KOSDAQ
• Ticker Symbol: 228760

Financial Performance

In 2024, Genomictree's revenue was 2.36 billion, a decrease of -30.89% compared to the previous year's 3.42 billion. Losses were -10.24 billion, 17.0% more than in 2023.